Mucoadhesive system formed by liquid crystals for buccal administration of poly(hexamethylene biguanide) hydrochloride

Journal of Pharmaceutical Sciences

Volumn 103, Issue 12, 2014, Pages 3914-3923

  Souza, Carla ^a   Watanabe, Evandro ^a   Borgheti Cardoso, Livia Neves ^a   De Fantini, Márcia Carvalho Abreu ^a   Lara, Marilisa Guimarães ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antimicrobial activity; Biomaterials; Controlled release; Lipids; Liquid crystal; Monoolein; Mucoadhesion; Mucosal drug delivery; PHMB; Surfactants

Indexed keywords

GLYCEROL OLEATE; POLY(HEXAMETHYLENEBIGUANIDE); ACYLGLYCEROL; ADHESIVE AGENT; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; GUANIDINE DERIVATIVE; POLY(HEXAMETHYLENEBIGUANIDINIUM); POLYMER;

ANTIBACTERIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHEEK MUCOSA; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; LIQUID CRYSTAL; MOUTH INFECTION; MUCOADHESION; NONHUMAN; STRENGTH; STREPTOCOCCUS MUTANS; SWELLING; WATER CONTENT; WATER SUPPLY; WATER TRANSPORT; ADMINISTRATION AND DOSAGE; BUCCAL DRUG ADMINISTRATION; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG EFFECTS; METABOLISM; MOUTH MUCOSA; PROCEDURES;

ADHESIVES; ADMINISTRATION, BUCCAL; ANTI-INFECTIVE AGENTS; CANDIDA ALBICANS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG DELIVERY SYSTEMS; GLYCERIDES; GUANIDINES; LIQUID CRYSTALS; MOUTH MUCOSA; POLYMERS;

EID: 84914816565     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24198     Document Type: Article

References (64)

1. Marsh P, Martin MV. 2005. Microbiologia oral. 4th ed. São Paulo: Livraria Santos Editora, pp 58-80.
2. Gajdziok J, Bajerová M, Chalupová Z, Rabišková M. 2010. Oxycellulose as mucoadhesive polymer in buccal tablets. Drug Dev Ind Pharm 36(9):1115-1130.
3. De Paula GF, Netto GI, Mattoso LHC. 2011. Physical and chemical characterization of poly(hexamethylene biguanide) hydrochloride. Polymers 3:928-941.
4. Hubner NO, Kramer A. 2010. Review on the efficacy, safety and clinical applications of polihexanide, a modern wound antiseptic. Skin Pharmacol Physiol 23(1):17-27.
5. Allen MJ, White GF, Morby AP. 2006. The response of Escherichia coli to exposure to the biocide polyhexamethylene biguanide. Microbiology 152:989-1000.
6. Rosin M, Welk A, Benhardt O, Ruhnau M, Pitten FA, Kocher T, Kramer A. 2001. Effect of a polyhexamethylene biguanide mouthrinse on bacterial counts and plaque. J Clin Periodontol 28:1121-1126.
7. Rosin M, Welk A, Kocher T, Majic-Todt A, Kramer A, Pitten FA. 2002. The effect of a polyhexamethylene biguanide mouthrinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth. J Clin Periodontol 98:392-399.
8. Nascimento AP, Tanomaru JMG, Matoba-Júnior F, Watanabe E, Tanomaru-Filho M, Ito IY. 2008. Maximum inhibitory diluition of mouthwashes containing clorhexidine and polyhexamethylene biguanide against salivary Staphylococcus aureus. J Appl Oral Sci 16(5):336-339.
9. Welk A, Splieth CH, Schmidt-Martens G, Schwahn CH, Kocher T, Kramer A, Rosin M. 2005. The effect of a polyhexamethylene biguanide mouthrinse compared with a triclosan rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque re-growth. J Clin Periodontol 32:499-505.
10. Koburger T, Hübner NO, Braun M, Siebert J, Kramer A. 2010. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 65:1712-1719.
11. Ulmer M, Patzelt A, Vergou T, Richter H, Müller G, Kramer A, Sterry W, Czaika V, Lademann J. 2013. In vivo investigation of the efficiency of a nanoparticle-emulsion containing polihexanide on the human skin. Eur J Pharm Biopharm 84:325-329.
12. Finger S, Wiegand C, Buschmann HJ, Hipler UC. 2013. Antibacterial properties of cyclodextrin-antiseptics-complexes determined by microplate laser nephelometry and ATP bioluminescence assay. Int J Pharm 452:188-193.
13. Loftsson T, Leeves N, Bjornsdottir B, Duffy L, Masson M. 1999. Effect of cyclodextrins and polymers on triclosan availability and substantivity in toothpastes in vivo. J Pharm Sci 88(12):1254-1258.
14. Geraghty PB, Attwood D, Collett JH, Dandiker Y. 1996. The in vitro release of some muscarinic drugs from monoolein/water lyotropic crystalline gels. Pharm Res 13:1265-1271.
15. Guo C, Wang J, Cao F, Lee RJ, Zhai G. 2010. Lyotropic liquid crystal systems in drug delivery. Drug Discov Today 15(23:24):1032-1040.
16. Shah JC, Sadhala Y, Chilukuri DM. 2001. Cubic phase as drug delivery systems. Adv Drug Deliv Rev 47:229-250.
17. Tyle P. 1989. Liquid crystal and their application in drug delivery. In Controlled release of drug: Polymers and aggregate systems. Vol. 4. New York: Morton Rosoff UHC Publishers, pp 125-162.
18. Sallam A, Khalil E, Ibrahim H, Freij I. 2002. Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate. Eur J Pharm Biopharm 53:343-352.
19. Burrows R, Collett JH, Attwood, D. 1994. The release of drugs from monoglyceride-water liquid crystalline phases. Int J Pharm 111:283-293.
20. Carr MG, Corish J, Corrigan OI. 1997. Drug delivery from a liquid crystalline base across Visking and human stratum corneum. Int J Pharm 157:35-42.
21. Phan S, Fong WK, Kirby N, Hanley T, Boyd BJ. 2011. Evaluation the link between self-assembledmesophase structure and drug release. Int J Pharm 421:176-182.
22. Engstrom S, Larsson K, Lindman B. 1988. Liquid crystalline phases as delivery systems for drugs: I. Basic principles. Control Release Bioac Mater 105.
23. Nielsen LS, Schubert L, Hansen J. 1998. Bioadhesive drug delivery systems. I. Chracterization of muco adhesive properties of systems based on glyceryl mono-oleate and glyceryl mono-linoleate. Eur J Pharm Sci 6:231-239.
24. Dash AK, Gong Z, Miller DW, Huai-Yan H, Laforet JP. 1999. Development of a rectal nicotine delivery system for the treatment of ulcerative colitis. Int J Pharm 190:21-34.
25. Lee J, Young SA, Kellaway IW. 2001. Water quantitatively induces the mucoadhesion of liquid crystalline phases of glyceryl monooleate. J Pharm Pharmacol 53:629-636.
26. Lee J, Kellaway IW. 2000. Buccal permeation of [D-Ala2, D-Leu5] enkephalin from liquid crystalline phases of glyceryl monooleate. Int J Pharm 195:35-38.
27. Norling T, Lading P, Engstron S, Larsson K, Krog N, Nissen SS. 1992. Formulation of a drug delivery system based on a mixture of monoglycerides and triglycerides for use in the treatment of periodontal disease. J Clin Periodontol 19:687-692.
28. Esposito E, Cartta V, Scabbia A, Trombelli L, D'antona P, Menegatti E, Nastruzzi C. 1996. Comparative analysis of tetracycline-containing dental gels: Poloxamer- and monoglyceride-based formulations. Int J Pharm 142:9-23.
29. Okonogi S, Khongkhunthain S, Bunyaratavej P, Thusaphorn T, Umpriwan R. 2004. Development of local injectable dental gel: The influence of certain additives on physicochemical properties of glycerylmonooleate-based Formulations. Drug Dev Ind Pharm 30(4):347-357.
30. Farkas E, Kiss D, Zelkó R. 2007. Study on the release of chlorhexidine base and salts from different liquid crystalline structures. Int J Pharm 340:71-75.
31. Bruschi ML, de Freitas O, Lara EH, Panzeri H, Gremião MP, Jones DS. 2008. Precursor system of liquid crystalline phase containing propolis microparticles for the treatment of periodontal disease: Development and characterization. Drug Dev Ind Pharm 34(3):267-278.
32. Moebusa K, Siepmannb J, Bodmeier R. 2012. Cubic phase-forming dry powders for controlled drug delivery on mucosal surfaces. J Control Release 157(2):206-215.
33. Rosevear FB. 1954. The microscopy of the liquid crystalline neat and middle phases of soaps and synthetic detergents. J Am Chem Soc 31:628-639.
34. Bertram U, Bodmeier R. 2006. In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro characterization of a new nasal dosage form. Eur J Pharm Sci 27:62-71.
35. Nakamoto RY. 1979. Use of a saliva substitute in postradiation xerostomia. J Prost Dent 42(5):539-542.
36. Schott H. 1992. Kinetics of swelling of polymers and their gels. J Pharm Sci 81:467-470.
37. Lee J, Choi S, Yoon MK, Chop YW. 2003. Kinetic characterization of swelling of liquid crystalline phases of glyceryl monooleate. Arch Pharm Res 2(10):880-885.
38. Schwartz JB, Simonelli AP, Higuchi WI. 1968. Drug release from wax matrices. I. Analysis of data with first-order kinetics and with the diffusion-controlled model. J Pharm Sci 57:274-277.
39. Rigter PL, Peppas NA. 1987. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J Control Release 5:37-42.
40. Grove DC, Randall WA. 1955. Assay methods of antibiotics: A laboratory manual (Antibiotics monographs, 02). New York: Medical Encyclopedia Inc., p 80.
41. Utyama IKA, Watanabe E, Andrade D, Ito IY. 2006. Atividade antimicrobiana in vitro doácido acético e dos vinagres branco e tinto sobre bactérias hospitalares. Rev Ciênc Méd Biol 5(2):111-116.
42. Rizwan SB, Hanley T, Boyd BJ, Rades T, Hook S. 2009. Liquid crystalline systems of phytantriol and glyceryl monooleate containing a hydrophilic protein: Characterisation, swelling and release kinetics. J Pharm Sci 98(11):4191-4204.
43. Dong YD, Boyd BJ. 2011. Applications of X-ray scattering in pharmaceutical science. Int J Pharm 417(1-2):101-111.
44. Amar-Yuli I, Wachtel E, Shoshan EB, Danino D, Aserin A, Garti N. 2007. Hexosome and hexagonal phases mediated by hidration and polymeric stabilizer. Langmuir 23:3637-3645.
45. Higuchi WI. 1962. Analysis of data on the medicament release from ointments. J Pharm Sci 51:802-804.
46. Clogston J, Rathman J, Thomasko D, Walker H, Caffrey M. 2000. Phase behavior of a monoacylglycerol (Myverol 18-99K)/water systems. Chem Phys Lipids 107:191-220.
47. Qiu H, Caffrey M. 2000. The phase diagram of the monoolein/water system: Metastability and equilibrium aspects. Biomaterials 21:223-234.
48. Engstrom S, Engstrom L. 1992. Phase behavior of the lidocaine-monoolein-water system. Int J Pharm 79:113-122.
49. Kumar MK, Shah MH, Ketkar A, Mahadik KR, Paradkar A. 2004. Effect of drug solubility and different excipients on floating behavior and release from glyceryl monooleate matrices. Int J Pharm 272:151-160.
50. Chang CM, Bodmeier R. 1998. Low viscosity monoglyceride-based drug delivery systems transforming into a highly viscous cubic phase. Int J Pharm 173:51-60.
51. Chang CM, Bodmeier R. 1997. Swelling of and drug release from monoglyceride-based drug delivery systems. J Pharm Sci 86:747-752.
52. Fong C, Le T, Drummond CJ. 2012. Lyotropic liquid crystal engineering-ordered nanostructured small molecule amphiphile self-assembly materials by design. Chem Soc Rev 41:1297-1322.
53. Rossetti FC, Fantini MC, Carollo AR, Tedesco AC, Bentley MVLB. 2011. Analysis of liquid crystalline nanoparticles by small angle X-ray diffraction: Evaluation of drug and pharmaceutical additives influence on the internal structure. J Pharm Sci 100(7):2849-2857.
54. Amar-Yuli I, Aserin A, Garti N. 2008. Solubilization of nutraceuticals into reverse hexagonal mesophases. J Phys Chem B 112:10171-10180.
55. Libster D, Aserin A, Wachtel E, Shoham G, Garti N. 2007. An HII liquid crystal-based delivery system for cyclosporine A: Physical characterization. J Colloid Sci 308:514-524.
56. Ikeda T, Ledwith A, Bamford CH, Hann RA. 1984. Interaction of a polymeric biguanide biocide with phospholipid membranes. Biochim Biophys Acta 769(1):57-66.
57. Borgheti-Cardoso LN, Deoieri LV, Diniz H, Calzzani RAJ, Fantini MCA, Iyomasa MM, Vicentini FTMC, Bentley MVLB. 2014. Self-assembling gelling formulation based on a crystalline-phase liquid as a non-viral vector for siRNA delivery. Eur J Pharm Sci 58:72-82.
58. Shah MH, Paradkar A. 2007. Effect of HLB of additives on the properties and drug release from the glyceryl monooleate matrices. Eur J Pharm Biopharm 67:166-174.
59. Lara MG, Bentley MVLB, Collett JH. 2005. In vitro drug release mechanism and drug loading studies of cubic phase gels. Int J Pharm 293:241-250.
60. Chang CM, Bodmeier R. 1997. Effect of dissolution media and additives on the drug release from cubic phase delivery systems. J Control Release 46:215-222.
61. Herbs N, Siebert J. 2007. In vitro efficacy of octenidine and polihexanide against biofilms composed of Pseudomonas aeruginosa. GMS Krankenhaushyg Interdiszip 2:Doc45(20071228).
62. Brecx M, Decker EM, Freitag HP, Maier G, Von Ohle C. 2008. The effect of polihexanide on dental biofilm formation in vivo. London, UK: Conf Pan Eur Fed Int Assoc Dent Res.
63. Herai H, Gratieri T, Thomazine JA, Bentley MVLB, Lopez RFVL. 2007. Doxorubicin skin penetration from monoolein-containing propylene glycol formulations. Int J Pharm 329:88-93.
64. Broxton P, Woodcock P, Heatley F, Gilbert P. 1984. Interaction of some polyhexamethylene biguanides and membrane phospholipids in Escherichia coli. J Appl Bacteriol 57(1):115-124.